Repurposing an FDA-Approved Drug to Inhibit Bacterial Protein Toxins

被引：0
|
作者：
Borho, J. [1 ]
Eckert, A. [1 ]
Koegel, M. [1 ]
Barth, H. [1 ]
机构：
[1] Univ Ulm Med Ctr, Inst Expt & Clin Pharmacol, Toxicol & Pharmacol Nat Prod, Ulm, Germany
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2024年 / 397卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P061
引用
收藏
页码：S32 / S32
页数：1
相关论文
共 50 条
  • [21] Repurposing of FDA-approved drugs as novel radiosensitisers in hypoxic prostate cancer
    Bibby, B.
    Thiruthaneeswaran, N.
    Yang, L.
    McArt, D.
    O'Reilly, P.
    Roberts, D.
    Choudhury, A.
    West, C.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S195 - S195
  • [22] In Silico and In Vitro Potential of FDA-Approved Drugs for Antimalarial Drug Repurposing against Plasmodium Serine Hydroxymethyltransferases
    Mee-udorn, Pitchayathida
    Phiwkaow, Kochakorn
    Tinikul, Ruchanok
    Sanachai, Kamonpan
    Maenpuen, Somchart
    Rungrotmongkol, Thanyada
    ACS OMEGA, 2023, 8 (39): : 35580 - 35591
  • [23] Computational and Experimental Drug Repurposing of FDA-Approved Compounds Targeting the Cannabinoid Receptor CB1
    Criscuolo, Emanuele
    De Sciscio, Maria Laura
    De Cristofaro, Angela
    Nicoara, Catalin
    Maccarrone, Mauro
    Fezza, Filomena
    PHARMACEUTICALS, 2023, 16 (12)
  • [24] FDA-approved drug repurposing screen identifies inhibitors of SARS-CoV-2 pseudovirus entry
    Singh, Manisha
    Shanmukha, Shruthi
    Eldesouki, Raghda E.
    Harraz, Maged M.
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [25] Drug repurposing for Alzheimer's disease: in silico and in vitro investigation of FDA-approved drugs as acetylcholinesterase inhibitors
    Kumar, Navneet
    Gahlawat, Anuj
    Kumar, Rajaram Naresh
    Singh, Yash Pal
    Modi, Gyan
    Garg, Prabha
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (07): : 2878 - 2892
  • [26] Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling
    Desai, Bansri
    Hong, Kyungwan
    Powers, John H.
    Doshi, Peter
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (01) : 377 - 379
  • [27] Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling
    Bansri Desai
    Kyungwan Hong
    John H. Powers
    Peter Doshi
    Journal of General Internal Medicine, 2020, 35 : 377 - 379
  • [28] FDA-APPROVED INDICATIONS
    ANDERSON, DA
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1984, 41 (11): : 2328 - 2328
  • [29] Prospects for repurposing FDA-approved medications as Omicron spike/ACE-2 protein complex disruptors
    Chandrasekaran, Jaikanth
    Parasuraman, Pavadai
    Theivendren, Panneerselvam
    Sundar, Krishnan
    Ammunje, Damodar Nayak
    Balaya, Rex Devasahayam Arokia
    Kunjiappan, Selvaraj
    JOURNAL OF RESEARCH IN PHARMACY, 2023, 27 (04): : 1605 - 1616
  • [30] Mebendazole: A candidate FDA approved drug for repurposing in leukaemia
    Matchett, K. B.
    Grishagin, I. V.
    Kettyle, L. M.
    Gavory, G.
    Harrison, T.
    Mills, K. I.
    Thompson, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 121 - 122
12345